Literature DB >> 15819722

StAR and progesterone producing enzymes (3beta-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage cytochromes P450) in human epithelial ovarian carcinoma: immunohistochemical and real-time PCR studies.

Manar Abd-Elaziz1, Takuya Moriya, Jun-ichi Akahira, Takashi Suzuki, Hironobu Sasano.   

Abstract

Steroidogenic acute regulatory protein (StAR), P450 side-chain cleavage enzyme (P450scc) and 3 beta-hydroxysteroid dehydrogenase enzyme (3beta-HSD) are all involved in the transport of cholesterol and production of progesterone. In situ production of sex steroids including progesterone have been considered to play important roles in pathogenesis and/or development of common epithelial ovarian carcinomas. In this study, StAR, P450scc, and 3beta-HSD were immunolocalized in 100 cases of ovarian carcinoma and results were then correlated with clinicopathological and prognostic parameters of individual patients including status of progesterone receptor (PR) in tumor cells. Results of immunohistochemistry were further characterized by real-time PCR analysis in 20 cases of epithelial ovarian carcinomas in which frozen tissues were available for examination. StAR, P450scc, and 3beta-HSD immunoreactivity was detected predominately in the cytoplasm of carcinoma cells. Results of real-time PCR analysis were correlated with those of immunohistochemical studies. StAR, P450scc, and 3beta-HSD H scores demonstrated significant inversed statistical correlation with FIGO stage, residual size of the tumor, and Ki67 LI. A positive statistically significant correlation was detected between StAR H score and PR-B LI. Multivariate statistical analysis demonstrated that the status of intratumoral StAR, FIGO stage, and residual tumor size all turned out to be independent prognostic factors for the clinical outcome of the patient. The presence of StAR, a cholesterol transporter for steroidogenesis in human epithelial ovarian carcinoma, may reflect the ability of these tumors to produce progesterone in situ that could influence biological behavior of these tumors, especially through progesterone dependent inhibition of tumor cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15819722     DOI: 10.1111/j.1349-7006.2005.00040.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  3 in total

1.  FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor.

Authors:  Y Li; S Ganta; C Cheng; R Craig; R R Ganta; L C Freeman
Journal:  Mol Cell Endocrinol       Date:  2007-01-16       Impact factor: 4.102

2.  The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer.

Authors:  Constanze Banz; Ute Ungethuem; Ralf-Juergen Kuban; Klaus Diedrich; Ernst Lengyel; Daniela Hornung
Journal:  Fertil Steril       Date:  2009-07-30       Impact factor: 7.329

3.  Genetic and epigenetic alterations of steroidogenic factor‑1 in ovarian tumors.

Authors:  Sarah Miller; Nobel Bhasin; Heather Urrego; Krzysztof Moroz; Brian G Rowan; Meera S Ramayya; Nick M Makridakis
Journal:  Int J Oncol       Date:  2012-12-28       Impact factor: 5.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.